Table 2.

Adjuvant treatment stratified on risk group.

Adjuvant Treatment	ESGO-ESTRO-ESP, ESMO	NCCN
Low	No adjuvant treatment recommended.	IA low grade (G1 or G2), no adjuvant treatment or vaginal brachytherapy if LVSI + and >/= 60 years IA high grade, vaginal brachytherapy + EBRT if LVSI+.
Intermediate	brachytherapy or EBRT
High-intermediate	RT + CHT (in cases of high grade and substantial LVSI) or brachytherapy alone (if LVSI - and stage II low grade endometrioid)
High	EBRT + CHT + brachytherapy boost if substantial LVSI, endocervical stromal invasion and/or stage IIIB-IIIC. or CHT All non-endometrioid carcinomas already included in high risk.	EBRT + CHT Clear cell/serous: stage IA with positive washings to stage IV, CHT +/− EBRT * Undifferentiated/dedifferentiated carcinoma or carcinosarcoma: CHT + EBRT/brachytherapy. * Unclear benefit of added CHT in stage I–II clear cell carcinomas
Advanced disease	Upfront surgery with tumor debulking if complete macroscopic resection is feasible with acceptable morbidity and QoL for the patient.